Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer (ATTRACT-2)

This study has been terminated.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: August 19, 2008
Last updated: December 29, 2015
Last verified: May 2012
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: No date given
  Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: May 1, 2012